Aug 01, 2025 7:45am EDT Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
Jul 09, 2025 7:50am EDT Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
Jul 07, 2025 7:45am EDT Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
Jun 30, 2025 7:45am EDT Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Jun 26, 2025 8:00am EDT Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Jun 05, 2025 9:00am EDT Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
Jun 02, 2025 9:00am EDT New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
May 13, 2025 8:00am EDT Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
Apr 28, 2025 8:45am EDT Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
